This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Blask, D. E. Articles by Zalatan, F. Search for Related Content PubMed PubMed Citation Articles by Blask, D. E. Articles by Zalatan, F.

Physiological Melatonin Inhibition of Human Breast Cancer Cell Growth in Vitro: Evidence for a Glutathione-mediated Pathway¹

Bassett Research Institute, Cooperstown, New York 13326-1394

Melatonin, the chief hormone secreted by the pineal gland, has been previously shown to inhibit human breast cancer cell growth at the physiological concentration of 1 nM in vitro. In this study, using the estrogen receptor (ER)-positive human breast tumor cell line MCF-7, we have shown that 10 µM L-buthionine-[S,R]-sulfoximine (L-BSO), an inhibitor of -glutamylcysteine synthetase (the rate-limiting enzyme in glutathione synthesis), blocks the oncostatic action of 1 nM melatonin over a 5-day incubation, indicating that glutathione is required for melatonin action. The result was repeated with ZR75-1 cells, suggesting that the glutathione requirement is a general phenomenon among ER⁺ breast cancer cells. Addition of exogenous glutathione (1 µM) to L-BSO-treated groups restored the melatonin response in both cell lines. Further demonstration of the importance of glutathione was shown using the ER^- breast tumor cell line HS578T, which is normally unresponsive to melatonin. Growth in this cell line was inhibited in the presence of 1 µM ethacrynic acid (an inhibitor of glutathione S-transferase) plus 1 nM melatonin, and this effect was blocked with 10 µM L-BSO. We also observed a steady decrease of intracellular glutathione in MCF-7 cells over a 5-day incubation, suggesting that these cells metabolize glutathione differently than do normal cells.

¹ Supported by the Stephen C. Clark Research Fund.

² To whom requests for Reprints should be addressed, at Bassett Research Institute, 1 Atwell Road, Cooperstown, NY 13326-1394.

Received 11/12/96. Accepted 3/24/97.

This article has been cited by other articles:

				T. Lialiaris, E. Lyratzopoulos, F. Papachristou, M. Simopoulou, C. Mourelatos, and N. Nikolettos Supplementation of melatonin protects human lymphocytes in vitro from the genotoxic activity of melphalan Mutagenesis, May 22, 2008; (2008) gen020v1. [Abstract] [Full Text] [PDF]

				F. Mahmoud, N. Sarhill, and M. A. Mazurczak The therapeutic application of melatonin in supportive care and palliative medicine American Journal of Hospice and Palliative Medicine, July 1, 2005; 22(4): 295 - 309. [Abstract] [PDF]

				J. Hansen Light at Night, Shiftwork, and Breast Cancer Risk J Natl Cancer Inst, October 17, 2001; 93(20): 1513 - 1515. [Full Text] [PDF]

				F. Zalatan, J. A. Krause, and D. E. Blask Inhibition of Isoproterenol-Induced Lipolysis in Rat Inguinal Adipocytes in Vitro by Physiological Melatonin via a Receptor-Mediated Mechanism Endocrinology, September 1, 2001; 142(9): 3783 - 3790. [Abstract] [Full Text] [PDF]

				R. Schiff, P. Reddy, M. Ahotupa, E. Coronado-Heinsohn, M. Grim, S. G. Hilsenbeck, R. Lawrence, S. Deneke, R. Herrera, G. C. Chamness, et al. Oxidative Stress and AP-1 Activity in Tamoxifen-Resistant Breast Tumors In Vivo J Natl Cancer Inst, December 6, 2000; 92(23): 1926 - 1934. [Abstract] [Full Text] [PDF]

				D. E. Blask, L. A. Sauer, R. T. Dauchy, E. W. Holowachuk, M. S. Ruhoff, and H. S. Kopff Melatonin Inhibition of Cancer Growth in Vivo Involves Suppression of Tumor Fatty Acid Metabolism via Melatonin Receptor-mediated Signal Transduction Events Cancer Res., September 1, 1999; 59(18): 4693 - 4701. [Abstract] [Full Text] [PDF]